Bedger, I am glad to hear that researchers " have significantly reduced the tumorigenicity potential of iPSCs" this is a good starting point.
I see positive signs for iPSC treatment in the future if absolute safety concerns are recognised and alleviated, but it is the FDA that needs to be convinced of this and not me.
A most recent article that is positive is linked below.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1457629/fullUnfortunately once again the same concerns are addressed.
2.4 Limitations of iPSC derived therapeutics
While iPSCs hold great promise for regenerative medicine, there are a few potential limitations that need to be addressed. First, iPSCs can be prone to genetic instability, including point mutations, copy number variations, and chromosomal rearrangements that can result from donor somatic cells, during reprogramming, or during extended cell culture (52,53). Residual undifferentiated iPSCs have the potential to form teratomas or other types of tumors if transplanted into patients (54). During the iPSC creation and differentiation process, routine genetic screening and monitoring are carried out utilizing high-throughput sequencing and other cutting-edge genomic technologies to identify and remove cells with genetic abnormalities. Advanced differentiation techniques can be developed to ensure that all iPSCs fully differentiate into the intended cell types, and the final differentiated cell products can be purified with selection in order to remove residual iPSCs. Furthermore, as discussed in section 3.1, suicide genes/safety switches can be inserted into iPSCs and activated to eradicate any undifferentiated iPSCs that may still exist, further improving the safety profile of iPSC derived cells.
So you can choose to ignore these concerns in the many published research findings, because you have CYP blinkers on, or you can accept that given so much evidence of these concerns, this treatment is years away, if ever, of convincing the FDA of its safety.
(20min delay)